ILT2

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Retrieved on: 
Tuesday, October 24, 2023

The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.

Key Points: 
  • The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
  • A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level.
  • The Phase 1a/b trial is expected to enroll over 120 patients.
  • "We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics.

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA

Retrieved on: 
Tuesday, October 17, 2023

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.

Key Points: 
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
  • ImmunOs is currently enrolling patients in the Phase 1a/b trial, initiated earlier this year, to evaluate the potential of IOS-1002 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced solid tumors.
  • “We are pleased to enter into this agreement for our ongoing Phase 1a/b trial of IOS-1002,” said Christoph Renner, M.D., Chief Medical Officer, and co-founder of ImmunOs.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002

Retrieved on: 
Wednesday, May 24, 2023

Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.

Key Points: 
  • Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the treatment of advanced solid tumors.
  • Primary endpoints of the current Phase 1a, first-in-human, open-label, non-randomized, multicenter study will be the safety and tolerability of IOS-1002.
  • "We are excited that our lead compound IOS-1002 has entered into a first-in-human trial and that patients are being dosed," said Sean R. Smith, CEO of ImmunOs Therapeutics.

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

Retrieved on: 
Tuesday, March 14, 2023

"Agenus has entered 2023 with strong momentum across our extensive and diverse clinical pipeline of immuno-oncology programs.

Key Points: 
  • "Agenus has entered 2023 with strong momentum across our extensive and diverse clinical pipeline of immuno-oncology programs.
  • Fourth Quarter and Full Year 2022 Financial Results:
    As of December 31, 2022, we had a cash, cash equivalent and short-term investment balance of $193 million, compared to $218 million and $307 million on September 30, 2022, and December 31, 2021, respectively.
  • For the fourth quarter ended December 31, 2022, we recognized revenue of $28 million and incurred a net loss of $74 million (including non-cash expenses of $33 million) or $0.24 per share.
  • Revenue includes revenue under our collaboration agreements, revenue related to non-cash royalties earned, milestones received, and revenue from Agenus owned CROs.

ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002

Retrieved on: 
Tuesday, January 17, 2023

In the trial, the compound will be administered at various dose levels to patients with advanced solid tumors either as monotherapy or in combination with a PD-1 monoclonal antibody.

Key Points: 
  • In the trial, the compound will be administered at various dose levels to patients with advanced solid tumors either as monotherapy or in combination with a PD-1 monoclonal antibody.
  • "Advancing our lead compound IOS-1002 into a first-in-human trial is a major milestone for our team and provides a potential new option for patients," said Sean R. Smith, CEO of ImmunOs Therapeutics.
  • "We are excited about the opportunity to evaluate IOS-1002 in patients, as the compound addresses key challenges in cancer immunotherapy.
  • We believe it has the potential to help patients with advanced solid tumors who have no further treatment options."

NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Retrieved on: 
Wednesday, December 7, 2022

The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).

Key Points: 
  • The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).
  • The Phase 2 portion of the trial will include expansion cohorts of patients treated with NGM707 in combination with KEYTRUDA (Part 2b) in several advanced solid tumor types.
  • The Part 1a arm enrolled patients into escalating NGM707 dose cohorts (6 mg to 1800 mg) administered intravenously every three weeks.
  • As of a November 23, 2022 data cut-off, 34 patients have been enrolled in the monotherapy dose escalation.

ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro

Retrieved on: 
Tuesday, November 15, 2022

November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.

Key Points: 
  • November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.
  • The presented data supports IOS-1002 as a first-in-class multi-functional agent which will enter a Phase 1 trial later this year.
  • "We are excited that our lead program IOS-1002 has generated such promising non-clinical data both as a monotherapy and in combination with anti-PD-1," added Sean R. Smith, Chief Executive Officer of ImmunOs Therapeutics.
  • ImmunOs lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.

Agenus Provides Corporate Update and Third Quarter 2022 Financial Report

Retrieved on: 
Tuesday, November 8, 2022

Ended quarter with $218 million in cash, cash equivalents and short-term investments

Key Points: 
  • Ended quarter with $218 million in cash, cash equivalents and short-term investments
    LEXINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancers and infectious disease, today provided a corporate update and reported financial results for the third quarter of 2022.
  • Cash used in operations was $32.2 million for the quarter ended September 30, 2022, and $128 million for the nine-months then ended.
  • We recognized revenue of $22.8 million and incurred a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022.
  • Non-cash operating expenses for the third quarter and nine-months ended September 30, 2022, were $22.2 million and $62.8 million respectively.

NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting

Retrieved on: 
Monday, November 7, 2022

NGM Bio anticipates enrolling approximately 220 patients in the trial.

Key Points: 
  • NGM Bio anticipates enrolling approximately 220 patients in the trial.
  • ILT2=Immunoglobulin-Like Transcript 2; ILT3=Immunoglobulin-Like Transcript 3; ILT4=Immunoglobulin-Like Transcript 4; LAIR1= LAIR1=Leukocyte-Associated Immunoglobulin-Like Receptor 1; LILR=Leukocyte Immunoglobulin-Like Receptor [ILT2 = LILRB1, ILT3=LILRB4, ILT4=LILRB2]; LIR=Leukocyte Immunoglobulin-Like Receptor.
  • NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease.
  • All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need.

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

Retrieved on: 
Tuesday, June 7, 2022

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.
  • "We are delighted to close this significant financing round led by a group of top-tier U.S. and European investors," said Sean R. Smith, CEO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.
  • ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.